Skip to main content

Table 4 Costs and utilities per 9-week Markov cycle for each model state

From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

State

Combination arm

Monotherapy arm

Cost/8 week ($)

QALY/8 week

Cost/8 week ($)

QALY/8 week

Stable disease

793,432.000

0.11076923

407,540.000

0.11230769

Treatment complication

801,398.177

0.11076923

410,717.085

0.11230769

Progression

00

0.09076923

0

0.09076923

Progression with complication

7966.17746

0.09076923

3177.08511

0.09076923

Death

0

0

0

0